Literature DB >> 21148557

Peroxisome proliferator-activated receptor gamma negatively regulates IFN-beta production in Toll-like receptor (TLR) 3- and TLR4-stimulated macrophages by preventing interferon regulatory factor 3 binding to the IFN-beta promoter.

Wei Zhao1, Lijuan Wang, Meng Zhang, Peng Wang, Lei Zhang, Chao Yuan, Jianni Qi, Yu Qiao, Paul C Kuo, Chengjiang Gao.   

Abstract

Toll-like receptors 3 and 4 utilize adaptor TRIF to activate interferon regulatory factor 3 (IRF3), resulting in IFN-β production to mediate anti-viral and bacterial infection. Peroxisome proliferator-activated receptor (PPAR)-γ is a ligand-activated transcription factor expressed in various immune cells and acts as a transcriptional repressor to inhibit the transcription of many proinflammatory cytokines. But, the function of PPAR-γ in TLR3- and -4-mediated IFN-β production is not well elucidated. Here, we have analyzed the effect of the PPAR-γ agonists on IFN-β production in peritoneal primary macrophages in response to LPS and poly(I:C). PPAR-γ agonists inhibited LPS and poly(I:C)-induced IFN-β transcription and secretion. siRNA knockdown of PPAR-γ expression and transfection of PPAR-γ expression plasmid demonstrated that PPAR-γ agonist inhibits IFN-β production in a PPAR-γ-dependent manner. The ability of the PPAR-γ agonist to inhibit IFN-β production was confirmed in vivo as mice treated with troglitazone exhibited decreased levels of IFN-β upon LPS and poly(I:C) challenge. Chromatin immunoprecipitation (CHIP) assay and electrophoretic mobility shift assay (EMSA) demonstrated that troglitazone treatment impaired IRF3 binding to the IFN-β promoter. Furthermore, troglitazone could inhibit LPS and poly(I:C)-induced STAT1 phosphorylation and subsequent ISRE activation. These results demonstrate that PPAR-γ negatively regulates IFN-β production in TLR3- and 4-stimulated macrophages by preventing IRF3 binding to the IFN-β promoter.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21148557      PMCID: PMC3037665          DOI: 10.1074/jbc.M110.149823

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  VISA is an adapter protein required for virus-triggered IFN-beta signaling.

Authors:  Liang-Guo Xu; Yan-Yi Wang; Ke-Jun Han; Lian-Yun Li; Zhonghe Zhai; Hong-Bing Shu
Journal:  Mol Cell       Date:  2005-09-16       Impact factor: 17.970

Review 2.  Type I interferon in systemic lupus erythematosus and other autoimmune diseases.

Authors:  Jacques Banchereau; Virginia Pascual
Journal:  Immunity       Date:  2006-09       Impact factor: 31.745

Review 3.  Innate immune recognition of viral infection.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Nat Immunol       Date:  2006-02       Impact factor: 25.606

4.  Essential role of interferon regulatory factor 3 in direct activation of RANTES chemokine transcription.

Authors:  R Lin; C Heylbroeck; P Genin; P M Pitha; J Hiscott
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

5.  Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus.

Authors:  Etienne Meylan; Joseph Curran; Kay Hofmann; Darius Moradpour; Marco Binder; Ralf Bartenschlager; Jürg Tschopp
Journal:  Nature       Date:  2005-09-21       Impact factor: 49.962

6.  Negative regulation of interferon-regulatory factor 3-dependent innate antiviral response by the prolyl isomerase Pin1.

Authors:  Tatsuya Saitoh; Adrian Tun-Kyi; Akihide Ryo; Masahiro Yamamoto; Greg Finn; Takashi Fujita; Shizuo Akira; Naoki Yamamoto; Kun Ping Lu; Shoji Yamaoka
Journal:  Nat Immunol       Date:  2006-05-14       Impact factor: 25.606

7.  IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction.

Authors:  Taro Kawai; Ken Takahashi; Shintaro Sato; Cevayir Coban; Himanshu Kumar; Hiroki Kato; Ken J Ishii; Osamu Takeuchi; Shizuo Akira
Journal:  Nat Immunol       Date:  2005-08-28       Impact factor: 25.606

8.  A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma.

Authors:  Gabriel Pascual; Amy L Fong; Sumito Ogawa; Amir Gamliel; Andrew C Li; Valentina Perissi; David W Rose; Timothy M Willson; Michael G Rosenfeld; Christopher K Glass
Journal:  Nature       Date:  2005-08-28       Impact factor: 49.962

9.  PPAR-gamma agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-kappaB pathways.

Authors:  Silke Appel; Valdete Mirakaj; Anita Bringmann; Markus M Weck; Frank Grünebach; Peter Brossart
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

10.  Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages.

Authors:  G Chinetti; S Griglio; M Antonucci; I P Torra; P Delerive; Z Majd; J C Fruchart; J Chapman; J Najib; B Staels
Journal:  J Biol Chem       Date:  1998-10-02       Impact factor: 5.157

View more
  23 in total

1.  The effect of fenofibrate, a PPARα activator on toll-like receptor-4 signal transduction in melanoma both in vitro and in vivo.

Authors:  N Dana; S Haghjooy Javanmard; G Vaseghi
Journal:  Clin Transl Oncol       Date:  2019-06-07       Impact factor: 3.405

Review 2.  The role of pattern recognition receptors in the innate recognition of Candida albicans.

Authors:  Nan-Xin Zheng; Yan Wang; Dan-Dan Hu; Lan Yan; Yuan-Ying Jiang
Journal:  Virulence       Date:  2015       Impact factor: 5.882

3.  USP4 positively regulates RIG-I-mediated antiviral response through deubiquitination and stabilization of RIG-I.

Authors:  Lijuan Wang; Wei Zhao; Meng Zhang; Peng Wang; Kai Zhao; Xueying Zhao; Shangru Yang; Chengjiang Gao
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

4.  PPARγ Deficiency Suppresses the Release of IL-1β and IL-1α in Macrophages via a Type 1 IFN-Dependent Mechanism.

Authors:  Kassandra J Weber; Madeline Sauer; Li He; Eric Tycksen; Gowri Kalugotla; Babak Razani; Joel D Schilling
Journal:  J Immunol       Date:  2018-08-24       Impact factor: 5.422

5.  PPARγ ameliorated LPS induced inflammation of HEK cell line expressing both human Toll-like receptor 4 (TLR4) and MD2.

Authors:  Reyhaneh Darehgazani; Maryam Peymani; Motahare-Sadat Hashemi; Mir Davood Omrani; Abolfazl Movafagh; Kamran Ghaedi; Mohammad Hossein Nasr-Esfahani
Journal:  Cytotechnology       Date:  2015-07-30       Impact factor: 2.058

6.  Nucleotide receptor P2RX7 stimulation enhances LPS-induced interferon-β production in murine macrophages.

Authors:  M L Gavala; Y-P Liu; L Y Lenertz; L Zeng; J B Blanchette; A G Guadarrama; L C Denlinger; P J Bertics; J A Smith
Journal:  J Leukoc Biol       Date:  2013-08-02       Impact factor: 4.962

7.  Lipids derived from virulent Francisella tularensis broadly inhibit pulmonary inflammation via toll-like receptor 2 and peroxisome proliferator-activated receptor α.

Authors:  Deborah D Crane; Robin Ireland; Joshua B Alinger; Pamela Small; Catharine M Bosio
Journal:  Clin Vaccine Immunol       Date:  2013-08-07

8.  Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune response.

Authors:  Rinath M Jeselsohn; Lillian Werner; Meredith M Regan; Aquila Fatima; Lauren Gilmore; Laura C Collins; Andrew H Beck; Shannon T Bailey; Housheng Hansen He; Gilles Buchwalter; Myles Brown; J Dirk Iglehart; Andrea Richardson; Steven E Come
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

9.  Network analysis identifies a putative role for the PPAR and type 1 interferon pathways in glucocorticoid actions in asthmatics.

Authors:  Diego Diez; Susumu Goto; John V Fahy; David J Erle; Prescott G Woodruff; Åsa M Wheelock; Craig E Wheelock
Journal:  BMC Med Genomics       Date:  2012-06-19       Impact factor: 3.063

10.  TRAF-interacting protein (TRIP) negatively regulates IFN-β production and antiviral response by promoting proteasomal degradation of TANK-binding kinase 1.

Authors:  Meng Zhang; Lijuan Wang; Xueying Zhao; Kai Zhao; Hong Meng; Wei Zhao; Chengjiang Gao
Journal:  J Exp Med       Date:  2012-09-03       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.